Oxygenta Pharmaceutical Ltd Stock Price Today (NSE: OXYGENTAPH)
Fundamental Score
Oxygenta Pharmaceutical Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Oxygenta Pharmaceutical Ltd share price today is ₹52.76, down 1.27% on NSE/BSE as of 16 September 2026. Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹195.12 (Cr). The 52-week high for OXYGENTAPH share price is ₹74.00 and the 52-week low is ₹43.00.
Oxygenta Pharmaceutical Ltd Share Price Chart — NSE/BSE Historical Performance
Oxygenta Pharmaceutical Ltd share price chart: -0.59% return over the past month. 52-week high ₹74.00, 52-week low ₹43.00.
Oxygenta Pharmaceutical Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹53.00 | ₹55.59 | ₹52.03 | ₹52.76 | 3.28K (Cr) | |
| ₹55.87 | ₹55.87 | ₹53.09 | ₹53.44 | 10.48K (Cr) | |
| ₹54.90 | ₹55.90 | ₹52.51 | ₹55.88 | 3.53K (Cr) | |
| ₹55.00 | ₹56.60 | ₹53.80 | ₹53.80 | 7.75K (Cr) | |
| ₹56.58 | ₹56.58 | ₹54.11 | ₹54.38 | 1.59K (Cr) | |
| ₹55.90 | ₹55.90 | ₹54.00 | ₹55.47 | 13.66K (Cr) | |
| ₹53.71 | ₹56.88 | ₹53.10 | ₹53.83 | 24.81K (Cr) | |
| ₹55.90 | ₹58.71 | ₹54.00 | ₹54.18 | 38.19K (Cr) | |
| ₹55.10 | ₹56.50 | ₹54.65 | ₹55.93 | 16.64K (Cr) | |
| ₹55.70 | ₹56.00 | ₹53.70 | ₹55.00 | 6.45K (Cr) |
Oxygenta Pharmaceutical Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹55.90 | ₹58.71 | ₹52.03 | ₹52.76 | -5.62% | |
| ₹50.06 | ₹71.59 | ₹48.80 | ₹59.48 | +18.82% | |
| ₹49.99 | ₹53.90 | ₹46.00 | ₹50.06 | +0.14% | |
| ₹53.95 | ₹53.95 | ₹43.00 | ₹48.49 | -10.12% | |
| ₹56.00 | ₹58.90 | ₹49.00 | ₹52.55 | -6.16% | |
| ₹45.30 | ₹64.80 | ₹45.30 | ₹54.34 | +19.96% | |
| ₹53.00 | ₹53.95 | ₹45.60 | ₹48.38 | -8.72% | |
| ₹57.39 | ₹64.00 | ₹46.60 | ₹53.40 | -6.95% | |
| ₹54.50 | ₹64.00 | ₹51.31 | ₹62.71 | +15.06% | |
| ₹61.04 | ₹64.89 | ₹52.10 | ₹55.79 | -8.60% | |
| ₹61.55 | ₹68.88 | ₹58.00 | ₹59.84 | -2.78% | |
| ₹69.98 | ₹71.75 | ₹53.56 | ₹63.68 | -9.00% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Oxygenta Pharmaceutical Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Oxygenta Pharmaceutical Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of OXYGENTAPH across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (65.61%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (144.47%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (16.77% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Balanced Promoter Holding (56.54%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Suboptimal ROCE (-52.12%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-11.44%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Weak Interest Coverage (-3.74x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.36)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-84.34 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.03%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Oxygenta Pharmaceutical Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Oxygenta Pharmaceutical Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Oxygenta Pharmaceutical LtdOxygenta Pharma...Selected✓ OXYGENTAPH • 524636 | 18.2/100 | ₹52.76₹53 | ₹195.12₹195.12 | — — | — — | -52.12%Poor -52.12% Poor | — — | — — | 16.77%Excellent 16.77% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Oxygenta Pharmaceutical Ltd PE Ratio History
Historical price-to-earnings ratio for OXYGENTAPH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2021 | ₹2.87 | ₹27.65 | 9.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Oxygenta Pharmaceutical Ltd Quarterly Performance
Latest quarterly metrics for OXYGENTAPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
144.47%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
65.61%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.77%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Oxygenta Pharmaceutical Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for OXYGENTAPH — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Oxygenta Pharmaceutical Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Oxygenta Pharmaceutical Ltd (OXYGENTAPH) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Oxygenta Pharmaceutical Ltd
About OXYGENTAPH (Oxygenta Pharmaceutical Ltd)
Oxygenta Pharmaceutical Ltd is a dynamic and innovative force within the Indian pharmaceutical landscape, committed to advancing healthcare solutions and enhancing patient well-bei...ng. With a foundation built on decades of experience, the company specializes in the research, development, and manufacturing of a diverse portfolio of high-quality pharmaceutical products. Oxygenta's core focus lies in addressing critical healthcare needs through the production of both established and novel therapeutic interventions. Its unwavering dedication to scientific rigor and ethical practices drives its pursuit of excellence in pharmaceutical innovation. Oxygenta endeavors to make a positive impact on the lives of individuals and communities across the nation. The company's robust infrastructure and state-of-the-art facilities, strategically located in Hyderabad, India, enable it to uphold the highest standards of quality and efficiency in its manufacturing processes. From meticulous sourcing of raw materials to stringent quality control measures, Oxygenta maintains a steadfast commitment to delivering safe and effective pharmaceuticals. Furthermore, Oxygenta actively fosters collaborations with research institutions and healthcare professionals to stay at the forefront of scientific advancements and address emerging healthcare challenges. By integrating cutting-edge technologies and innovative approaches, Oxygenta strives to develop groundbreaking therapies that improve patient outcomes and transform the healthcare landscape. Oxygenta Pharmaceutical Ltd also understands the vital role of access to medicines and its importance in the ecosystem. With a deeply ingrained sense of social responsibility, the company is dedicated to making its pharmaceutical products accessible and affordable to a wide range of patients. Oxygenta strives to contribute to the overall health and prosperity of the nation. Guided by a strong ethical compass and a passion for improving lives, Oxygenta continues to make great strides as a trusted partner in healthcare, driven by a vision of a healthier future for all.
Company Details
Key Leadership
OXYGENTAPH Share Price: Frequently Asked Questions
What is the current share price of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) trades at ₹52.76 on NSE and BSE. Market cap ₹195.12 (Cr). Educational data only.
What is the P/E ratio of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd has a Bull Run score of 18.2/100 based on 25+ financial parameters.
Does Oxygenta Pharmaceutical Ltd pay dividends?
Oxygenta Pharmaceutical Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd has debt-to-equity of N/A.
Is Oxygenta Pharmaceutical Ltd a good investment?
Bull Run gives Oxygenta Pharmaceutical Ltd a score of 18.2/100. This is not investment advice — consult a SEBI-registered advisor.